Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Short term Debt (2022 - 2023)

TriSalus Life Sciences has reported Short term Debt over the past 2 years, most recently at $10.0 million for Q2 2023.

  • For Q2 2023, Short term Debt changed N/A year-over-year to $10.0 million; the TTM value through Jun 2023 reached $10.0 million, changed N/A, while the annual FY2022 figure was $2.5 million, N/A changed from the prior year.
  • Short term Debt for Q2 2023 was $10.0 million at TriSalus Life Sciences, up from $4.7 million in the prior quarter.
  • Over five years, Short term Debt peaked at $10.0 million in Q2 2023 and troughed at $2.5 million in Q4 2022.